Surgical Science Sweden AB (publ) (STO:SUS)
Sweden · Delayed Price · Currency is SEK 38.20
+0.92 (2.47%)
Aug 14, 2026, 5:29 PM CET
STO:SUS Ratios and Metrics
Market cap in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,949 | 1,658 | 7,955 | 9,312 | 8,367 | 14,301 | |
Market Cap Growth | -61.99% | -79.15% | -14.57% | 11.30% | -41.49% | 343.39% |
Enterprise Value | 1,284 | 1,063 | 7,289 | 8,706 | 7,997 | 13,990 |
Last Close Price | 38.20 | 32.50 | 155.90 | 182.50 | 164.70 | 281.50 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 37.33 | 24.82 | 60.43 | 39.80 | 44.51 | 165.81 |
Forward PE | 15.28 | 14.63 | 34.77 | 40.02 | 54.94 | 157.93 |
PS Ratio | 1.99 | 1.67 | 9.00 | 10.55 | 10.43 | 38.99 |
PB Ratio | 0.44 | 0.39 | 1.65 | 2.14 | 1.98 | 3.99 |
P/TBV Ratio | 2.09 | 1.85 | 8.83 | 12.76 | 17.04 | 49.01 |
P/FCF Ratio | 14.86 | 24.35 | 60.67 | 40.87 | 69.65 | 406.13 |
P/OCF Ratio | 12.99 | 20.78 | 57.97 | 39.08 | 64.62 | 365.90 |
PEG Ratio | - | 1.74 | 1.74 | 1.74 | 1.74 | 1.74 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.31 | 1.07 | 8.24 | 9.86 | 9.96 | 38.14 |
EV/EBITDA Ratio | 7.68 | 6.68 | 42.99 | 41.04 | 45.06 | 141.31 |
EV/EBIT Ratio | 11.49 | 8.07 | 50.54 | 46.03 | 50.98 | 168.60 |
EV/FCF Ratio | 9.79 | 15.60 | 55.59 | 38.21 | 66.57 | 397.31 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.01 | 0.30 | 0.31 | 0.18 | 0.08 | 0.11 |
Debt / FCF Ratio | 0.02 | 0.83 | 0.43 | 0.18 | 0.12 | 0.34 |
Net Debt / Equity Ratio | -0.15 | -0.13 | -0.19 | -0.14 | -0.10 | -0.08 |
Net Debt / EBITDA Ratio | -4.75 | -3.52 | -5.37 | -2.80 | -2.36 | -3.08 |
Net Debt / FCF Ratio | -5.07 | -8.22 | -6.95 | -2.61 | -3.49 | -8.65 |
Asset Turnover | 0.20 | 0.20 | 0.17 | 0.19 | 0.19 | 0.17 |
Inventory Turnover | 1.71 | 1.74 | 1.71 | 1.87 | 2.19 | 1.61 |
Quick Ratio | 3.25 | 3.28 | 2.39 | 3.52 | 2.22 | 2.14 |
Current Ratio | 4.47 | 4.05 | 2.78 | 4.22 | 2.70 | 2.66 |
Return on Equity (ROE) | 1.17% | 1.47% | 2.87% | 5.45% | 4.81% | 4.30% |
Return on Assets (ROA) | 1.44% | 1.62% | 1.77% | 2.53% | 2.27% | 2.33% |
Return on Invested Capital (ROIC) | 2.07% | 2.30% | 3.13% | 4.36% | 3.99% | 4.58% |
Return on Capital Employed (ROCE) | 2.50% | 3.00% | 2.90% | 4.20% | 3.60% | 2.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.68% | 4.03% | 1.65% | 2.51% | 2.25% | 0.60% |
FCF Yield | 6.73% | 4.11% | 1.65% | 2.45% | 1.44% | 0.25% |
Buyback Yield / Dilution | - | - | -0.17% | -0.05% | -19.32% | -24.14% |